Sökning: WFRF:(Weston David J.) > Diabetic patients w...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06114naa a2200757 4500 | |
001 | oai:lup.lub.lu.se:04d2dcf7-6fab-4ab7-9f9d-7bf7b0a175ff | |
003 | SwePub | |
008 | 190523s2017 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/04d2dcf7-6fab-4ab7-9f9d-7bf7b0a175ff2 URI |
024 | 7 | a https://doi.org/10.1093/ehjcvp/pvw0492 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Lettino, Maddalenau Humanitas Research Hospital4 aut |
245 | 1 0 | a Diabetic patients with acute coronary syndromes in contemporary European registries : Characteristics and outcomes |
264 | c 2017-03-10 | |
264 | 1 | b Oxford University Press (OUP),c 2017 |
520 | a Aims Among patients with acute coronary syndromes (ACS), those with diabetes mellitus (DM) are at particularly high risk of recurrent cardiovascular events and premature death. We aimed to provide a descriptive overview of unadjusted analyses of patient characteristics, ACS management, and outcomes up to 1 year after hospital admission for an ACS/index-ACS event, in patients with DM in contemporary registries in Europe. Methods and results A total of 10 registries provided data in a systematic manner on ACS patients with DM (total n =28 899), and without DM (total n= 97 505). In the DM population, the proportion of patients with ST-Segment Elevation Myocardial Infarction (STEMI) ranged from 22.1% to 64.6% (other patients had non-ST-Segment Elevation Myocardial Infarction (NSTEMI-ACS) or unstable angina). All-cause mortality in the registries ranged from 1.4% to 9.4% in-hospital; 2.8% to 7.9% at 30 days post-discharge; 5.1% to 10.7% at 180 days post-discharge; and 3.3% to 10.5% at 1 year post-discharge. Major bleeding events were reported in up to 3.8% of patients while in hospital (8 registries); up to 1.3% at 30 days (data from two registries only), and 2.0% at 1 year (one registry only). Registries differed substantially in terms of study setting, site, patient selection, definition and schedule of endpoints, and use of various P2Y12 inhibitors. In most, but not all, registries, event rates in DM patients were higher than in patients without DM. Pooled risk ratios comparing cohorts with DM vs. no DM were in-hospital significantly higher in DM for all-cause death (1.66; 95% CI 1.42-1.94), for cardiovascular death (2.33; 1.78 - 3.03), and for major bleeding (1.35; 1.21-1.52). Conclusion These registry data from real-life clinical practice confirm a high risk for recurrent events among DM patients with ACS, with great variation across the different registries. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng |
653 | a Acute coronary syndromes | |
653 | a Antiplatelets | |
653 | a Clopidogrel | |
653 | a Diabetes mellitus | |
653 | a Non-ST-segment elevation | |
653 | a Observational | |
653 | a P2Y12 receptor inhibitors | |
653 | a Prasugrel | |
653 | a ST-segment elevation | |
653 | a Ticagrelor | |
653 | a Type 2 diabetes | |
653 | a Unstable angina | |
700 | 1 | a Andell, Pontusu Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital4 aut0 (Swepub:lu)med-poa |
700 | 1 | a Zeymer, Uweu Klinikum Ludwigshafen4 aut |
700 | 1 | a Widimsky, Petru Charles University in Prague4 aut |
700 | 1 | a Danchin, Nicolasu Paris Descartes University4 aut |
700 | 1 | a Bardaji, Alfredo4 aut |
700 | 1 | a Barrabes, Jose A.u Vall d'Hebron University Hospital4 aut |
700 | 1 | a Cequier, Angelu Bellvitge University Hospital-IDIBELL4 aut |
700 | 1 | a Claeys, Marc J.u Antwerp University Hospital4 aut |
700 | 1 | a De Luca, Leonardo4 aut |
700 | 1 | a Dörler, Jakob4 aut |
700 | 1 | a Erlinge, Davidu Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Molekylär kardiologi,Forskargrupper vid Lunds universitet,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Molecular Cardiology,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)kard-der |
700 | 1 | a Erne, Paulu University of Zurich4 aut |
700 | 1 | a Goldstein, Patricku University of Lille4 aut |
700 | 1 | a Koul, Sasha M.u Lund University,Lunds universitet,Molekylär kardiologi,Forskargrupper vid Lunds universitet,Molecular Cardiology,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)med-sku |
700 | 1 | a Lemesle, Gillesu University of Lille4 aut |
700 | 1 | a Lüscher, Thomas F.u University Hospital of Zurich4 aut |
700 | 1 | a Matter, Christian M.u University Hospital of Zurich4 aut |
700 | 1 | a Montalescot, Gillesu Pitié-Salpêtrière University Hospital4 aut |
700 | 1 | a Radovanovic, Draganau University of Zurich4 aut |
700 | 1 | a Sendón, Jose Lopezu University Hospital La Paz4 aut |
700 | 1 | a Tousek, Petr4 aut |
700 | 1 | a Weidinger, Franzu Hospital Rudolfstiftung4 aut |
700 | 1 | a Weston, Clive F.M.u Swansea University4 aut |
700 | 1 | a Zaman, Azfaru Freeman Hospital4 aut |
700 | 1 | a Li, Jinu University Hospital of Zurich4 aut |
700 | 1 | a Jukema, J. Wouteru Leiden University Medical Centre4 aut |
710 | 2 | a Humanitas Research Hospitalb Kardiologi4 org |
773 | 0 | t European Heart Journal - Cardiovascular Pharmacotherapyd : Oxford University Press (OUP)g 3:4, s. 198-213q 3:4<198-213x 2055-6837x 2055-6845 |
856 | 4 | u http://dx.doi.org/10.1093/ehjcvp/pvw049x freey FULLTEXT |
856 | 4 | u https://academic.oup.com/ehjcvp/article-pdf/3/4/198/19785227/pvw049.pdf |
856 | 4 8 | u https://lup.lub.lu.se/record/04d2dcf7-6fab-4ab7-9f9d-7bf7b0a175ff |
856 | 4 8 | u https://doi.org/10.1093/ehjcvp/pvw049 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy